PMID- 31984255
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240328
IS  - 2470-1343 (Electronic)
IS  - 2470-1343 (Linking)
VI  - 5
IP  - 2
DP  - 2020 Jan 21
TI  - Cancer Cell Membrane-Decorated Zeolitic-Imidazolate Frameworks Codelivering 
      Cisplatin and Oleanolic Acid Induce Apoptosis and Reversed Multidrug Resistance 
      on Bladder Carcinoma Cells.
PG  - 995-1002
LID - 10.1021/acsomega.9b02261 [doi]
AB  - Combination therapy is emerging as a preferable approach in cancer therapy with 
      minimized side effects and elevated performance. Nevertheless, the poor targeting 
      and drug loading of currently available drug delivery systems (DDSs) are the main 
      difficulties to realize preferable combination therapy of cancer. As a result, a 
      cancer cell membrane-decorated zeolitic-imidazolate framework hybrid nanoparticle 
      (HP) was successfully constructed in our study to codeliver cisplatin (DDP) and 
      oleanolic acid (OLA). Our results showed positive results of the platform 
      (HP/DDP/OLA) for the treatment of bladder cancer (SW780). In detail, HP/DDP/OLA 
      could enhance apoptosis while reverse multidrug resistance in SW780 cells than 
      free drugs alone or monodelivery systems, which might be a suitable DDS for 
      codelivery of different drugs with great promise.
CI  - Copyright (c) 2020 American Chemical Society.
FAU - Chen, Dong
AU  - Chen D
AD  - Department of Urology, 2nd Affiliated Hospital of Fujian Medical University, 
      Quanzhou City 362000, Fujian Province, China.
FAU - Cai, Longbo
AU  - Cai L
AD  - Department of Urology, 2nd Affiliated Hospital of Fujian Medical University, 
      Quanzhou City 362000, Fujian Province, China.
FAU - Guo, Yihong
AU  - Guo Y
AD  - Department of Urology, 2nd Affiliated Hospital of Fujian Medical University, 
      Quanzhou City 362000, Fujian Province, China.
FAU - Chen, Junyi
AU  - Chen J
AD  - Department of Urology, 2nd Affiliated Hospital of Fujian Medical University, 
      Quanzhou City 362000, Fujian Province, China.
FAU - Gao, Qiangli
AU  - Gao Q
AD  - Department of Urology, The Affiliated Puren Hospital of Wuhan University of 
      Science and Technology, No. 1 Benxi Street, the Fourth Jianshe Road, Qingshan 
      District, Wuhan 430080, China.
FAU - Yang, Junxian
AU  - Yang J
AD  - Department of Urology, The Affiliated Puren Hospital of Wuhan University of 
      Science and Technology, No. 1 Benxi Street, the Fourth Jianshe Road, Qingshan 
      District, Wuhan 430080, China.
FAU - Li, Yongfa
AU  - Li Y
AD  - Department of Urology, The Affiliated Puren Hospital of Wuhan University of 
      Science and Technology, No. 1 Benxi Street, the Fourth Jianshe Road, Qingshan 
      District, Wuhan 430080, China.
LA  - eng
PT  - Journal Article
DEP - 20200106
PL  - United States
TA  - ACS Omega
JT  - ACS omega
JID - 101691658
PMC - PMC6977025
COIS- The authors declare no competing financial interest.
EDAT- 2020/01/28 06:00
MHDA- 2020/01/28 06:01
PMCR- 2020/01/06
CRDT- 2020/01/28 06:00
PHST- 2019/07/22 00:00 [received]
PHST- 2019/09/11 00:00 [accepted]
PHST- 2020/01/28 06:00 [entrez]
PHST- 2020/01/28 06:00 [pubmed]
PHST- 2020/01/28 06:01 [medline]
PHST- 2020/01/06 00:00 [pmc-release]
AID - 10.1021/acsomega.9b02261 [doi]
PST - epublish
SO  - ACS Omega. 2020 Jan 6;5(2):995-1002. doi: 10.1021/acsomega.9b02261. eCollection 
      2020 Jan 21.